Vantrelatmer is a long-term opioid treatment for severe pain. The drug is intended for use only when alternative treatment options fail to control pain.
The drug contains abuse-deterrent properties against the three most common routes of abuse: oral, intranasal and intravenous.
“Teva understands the risk of prescription drug abuse is a challenge healthcare professionals face when treating millions of Americans affected by chronic pain,” said Rob Koremans, MD, president and CEO of global specialty medicines at Teva. “Abuse-deterrent treatments provide options for prescribers that may help deter or mitigate abuse while still preserving access to pain medications for the patients that need them most.”
More articles on supply chain:
Washington, D.C.-area hospitals desperate for blood donations ahead of inauguration
Target invests in supply chain tech startup
4 ways the FDA is working to boost diversity in clinical trials
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.